We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Nanoscale DNA Sequencing Could Trigger Transformation in Personal Healthcare

By LabMedica International staff writers
Posted on 15 Sep 2010
In experiments with potentially far-ranging healthcare implications, a research team has devised a method that works at a very small scale to sequence DNA rapidly and comparatively inexpensively. More...
That could create new opportunities for more effective individualized medicine, for example, providing blueprints of genetic predispositions for specific conditions and diseases such as cancer, diabetes, or addiction.

"The hope is that in 10 years people will have all their DNA sequenced, and this will lead to personalized, predictive medicine,” said Dr. Jens Gundlach, a University of Washington (UW; Seattle, USA) physics professor and lead author of a paper describing the new technique published the week of August 16, 2010, in the Proceedings of the [U.S.] National Academy of Sciences (PNAS).

The technique creates a DNA reader that combines biology and nanotechnology emplying a nanopore taken from Mycobacterium smegmatis porin A. The nanopore has an opening one billionth of a meter in size, just large enough to measure a single strand of DNA as it passes through. The scientists placed the pore in a membrane surrounded by potassium-chloride solution. A small voltage was applied to create an ion current flowing through the nanopore, and the current's electrical signature altered depending on the nucleotides traveling through the nanopore. Each of the nucleotides that are the basis of DNA-- cytosine, guanine, adenine, and thymine--generated a distinguishing signature.

The investigators had to solve two major hurdles. One was to create a short and narrow opening just large enough to allow a single strand of DNA to pass through the nanopore and for only a single DNA molecule to be in the opening at any time. Dr. Michael Niederweis, from the University of Alabama at Birmingham (USA), engineered the M. smegmatis bacterium to produce a suitable pore.

The second problem, according to Dr. Gundlach, was that the nucleotides flowed through the nanopore at a rate of one every millionth of a second, far too fast to sort out the signal from each DNA molecule. To compensate, the researchers attached a section of double-stranded DNA between each nucleotide they wanted to measure. The second strand would briefly catch on the edge of the nanopore, stopping the flow of DNA long enough for the single nucleotide to be held within the nanopore DNA reader. After a few milliseconds, the double-stranded section would separate and the DNA flow continued until another double strand was encountered, allowing the next nucleotide to be read.

The delay, although measured in thousandths of a second, is long enough to read the electrical signals from the target nucleotides, according to Dr. Gundlach. "We can practically read the DNA sequence from an oscilloscope trace,” he said.

The work was funded by the U.S. National Institutes of Health and its National Human Genome Research Institute (Bethesda, MD, USA) as part of a program to create technology to sequence a human genome for US$1,000 or less. That program began in 2004, when it cost approximately $10 million to sequence a human-sized genome.

The new research, according to the scientists, is a key step toward achieving DNA sequencing at a cost of $1,000 or less. "Our experiments outline a novel and fundamentally very simple sequencing technology that we hope can now be expanded into a mechanized process,” Dr. Gundlach concluded.

Related Links:
University of Washington
University of Alabama at Birmingham


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Integrated Biochemical & Immunological System
Biolumi CX8
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.